Travere Therapeutics Financials - Benzinga

Travere Therapeutics Inc

TVTXNASDAQ

Trade with Public

Trade with Public

$58.50

-0.94-1.58%

Últ. Act.: Sep 28, 9:26 AM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Travere Therapeutics Financials

Travere Therapeutics (TVTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales gains outweighed earnings concerns.

Mohd Haider

PRO
Travere Therapeutics Q2 Adj. EPS $(0.10) Beats $(0.14) Estimate, Sales $169.584M Beat $159.589M Estimate

Benzinga Newsdesk

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets.

Avi Kapoor

PRO
Travere Therapeutics Q1 Adj. EPS $0.05 Beats $(0.26) Estimate, Sales $127.199M Miss $136.822M Estimate.

Travere Therapeutics (NASDAQ:TVTX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.26) by 119.23 percent. This is a 126.32 percent increase over losses of $(0.19) per share

Benzinga Newsdesk

Earnings Scheduled For May 4, 2026

Benzinga Insights

Travere Therapeutics Q4 Earnings Report: What Investors Need to Know

Benzinga Insights

© 2026 Benzinga | All Rights Reserved